Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HS235 · 2 trials · 3 indications
An AE is any untoward medical occurrence in a participant or clinical trial participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The incidence and number of participants who experience an AE will be reported.
| Arm | Type | Description |
|---|---|---|
| Investigational Product | EXPERIMENTAL | HS235 Subcutaneous Injection |
| Placebo | PLACEBO_COMPARATOR | Subcutaneous Injection |
| HS235 | EXPERIMENTAL | HS235 Subcutaneous Injection |
| Name | Type | Description |
|---|---|---|
| HS235 | BIOLOGICAL | Subcutaneous Injection |
| Placebo | OTHER | Subcutaneous Injection |
Inclusion Criteria: Participants are eligible to be included in the study only if they meet at least all the following criteria: 1. Male or female, ≥ 18 years of age. 2. \[Sub-population A only - using a remote PAP sensor\]- Ambulatory PAP monitoring (e.g., CardioMEMS™ HF System or Cordella™ HF Sy...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| United Therapeutics Corporation | UTHR | 5 | PHASE3 | Ralinepag |
| Merck & Co., Inc. | MRK | 6 | PHASE3 | Riociguat |
| Insmed Incorporated | INSM | 4 | PHASE3 | Treprostinil Palmitil |
| Johnson & Johnson | JNJ | 4 | PHASE3 | Selexipag |
| Liquidia Corporation | LQDA | 4 | PHASE3 | L606 |
| Tenax Therapeutics, Inc. | TENX | 3 | PHASE3 | TNX-103 |
| Inhibikase Therapeutics, Inc. | IKT | 1 | PHASE3 | IKT-001 |
| Gossamer Bio, Inc. | GOSS | 2 | PHASE3 | Seralutinib |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | REGN13335 |
| Pfizer Inc. | PFE | 1 | PHASE2 | PF-07868489 |
| Tectonic Therapeutic Inc | TECX | 1 | PHASE2 | TX000045- Dose A, TX000045- Dose B |
| Abbott Laboratories | ABT | 1 | N/A | Undisclosed |
HS235 is an investigational monoclonal antibody being developed for pulmonary arterial hypertension (PAH) and pulmonary hypertension. It is also being studied in obese participants with pulmonary hypertension and heart failure with preserved ejection fraction (HFpEF). The drug is in Phase 1 clinical development.
HS235 is being developed by GSK plc, a biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting Phase 1 clinical trials of HS235 in the United States and Spain.
HS235 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. Two Phase 1 trials are currently recruiting participants to evaluate the drug for pulmonary arterial hypertension and pulmonary hypertension with HFpEF.
HS235 is being studied in two Phase 1 clinical trials. NCT07123779 is a study in obese participants with pulmonary hypertension and heart failure with preserved ejection fraction, enrolling 126 participants in the United States. NCT07143448 is a study for pulmonary arterial hypertension in adults, enrolling 90 participants in the United States and Spain.
HS235 is a distinct investigational monoclonal antibody. No alternative names for HS235 have been disclosed in clinical trial records. It is being studied under its own name in ongoing Phase 1 trials for pulmonary hypertension conditions.